(WVE)
NGM – Real vaqt narxi. Valyuta: USD
6.37
+0.17 (2.66%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
6.40
+0.04 (0.55%)
Bozordan keyin: Mar 27, 2026, 7:56 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
6.37
+0.17 (2.66%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
6.40
+0.04 (0.55%)
Bozordan keyin: Mar 27, 2026, 7:56 PM EDT
Wave Life Sciences Ltd., klinik bosqichdagi biotexnologiya kompaniyasi, PRISM, kashfiyot va dori vositalarini ishlab chiqish platformasi orqali ribonuklein kislotasi (RNA) dorilarini ishlab chiqadi, rivojlantiradi va tijoratlashtiradi. Kompaniyaning PRISM dorilari platformasi noyob va keng tarqalgan kasalliklarni davolashda ilmiy yutuqlarga erishish uchun ko'plab modaliteler, kimyo innovatsiyalari va inson genetikasini chuqur tushunishni birlashtiradi. Kompaniya alfa-1 antitripsin etishmovchiligini davolash uchun GalNAc-konjugatsiyalangan RNK tahrirlovchi oligonukleotidi bo'lgan WVE-006; semizlikka qarshi INHBE mRNA ni sukut holatiga keltirish uchun mo'ljallangan GalNAc-konjugatsiyalangan kichik interferentsiya qiluvchi RNK bo'lgan WVE-007; jigar kasalliklarini davolash uchun GalNAc-konjugatsiyalangan RNK tahrirlovchi oligonukleotidi bo'lgan WVE-008; Duchenne mushak distrofiyasini davolash uchun exon splicing oligonukleotidi bo'lgan WVE-N531; va Huntington kasalligini (HD) davolash uchun allel-selektiv oligonukleotidi bo'lgan WVE-003 ni ishlab chiqmoqda. Kompaniya oligonukleotidli terapevtik vositalarni tadqiq qilish, ishlab chiqish va tijoratlashtirish bo'yicha GlaxoSmithKline; Markaziy asab tizimi kasalliklari uchun oligonukleotidli terapevtik vositalarni tadqiq qilish, ishlab chiqish va tijoratlashtirish bo'yicha Takeda Pharmaceutical Company Limited; va HD ga yo'naltirilgan tadqiq qilinayotgan allel-selektiv terapevtik dasturlar uchun hamroh diagnostikasini ishlab chiqish va potentsial tijoratlashtirish bo'yicha Asuragen, Inc. bilan hamkorlik shartnomalariga ega. Wave Life Sciences Ltd. 2012 yilda tashkil etilgan va Singapurda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer |
| Dr. Christopher Francis Ph.D. | Senior VP of Corporate Development & Head of Emerging Areas |
| Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer |
| Dr. Gregory L. Verdine Ph.D. | Founder & Director |
| Dr. Paul B. Bolno M.B.A., M.D. | President, CEO & Director |
| Dr. Sridhar Vaddeboina M.B.A., Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls |
| Mr. Kyle B. Moran CFA | CFO & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-02-02 | 8-K | d78838d8k.htm |
| 2026-01-12 | 8-K | d45710d8k.htm |
| 2025-11-17 | 8-K | d68638d8k.htm |
| 2025-11-10 | S-8 | d22976ds8.htm |
| 2025-10-30 | 8-K/A | d59691d8ka.htm |
| 2025-10-29 | 8-K | d95356d8k.htm |
| 2025-09-24 | 8-K | d76224d8k.htm |
| 2025-09-03 | 8-K | d67509d8k.htm |
| 2025-08-11 | 8-K | d35789d8k.htm |
| 2025-08-05 | 8-K | d39256d8k.htm |
| Ms. Daryn Lewis | Senior VP & Head of Human Resources |
| Ms. Kate Rausch | Head of Investor Relations |
| Ms. Linda Rockett J.D. | Senior VP & General Counsel |